Summary
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
History
Spruce Biosciences was founded in 2014 by scientists, industry veterans, and clinicians to bridge the gap between genetic technologies and treatments for patients with rare, often serious diseases. Since then, we have been developing personalized therapies that target the underlying genetic causes of each patient’s disease.
Mission
To use data to develop novel, unique, and personalized small molecule drugs targeting the underlying genetic cause of disease.
Vision
We envision a world in which treatments are tailored specifically to each patient and their unique genetic profile.
Key Team
Dr. Ralph William Charlton III, M.D. (Chief Medical Officer)
Ms. P. J. Ramtin (Sr. VP of Bus. Operations)
Recognition and Awards
Spruce Biosciences has been selected to participate in the 2020 FierceBioTech Innovator program and was named as one of the 2020 CB Insights Digital Health 150 companies. We have been featured in publications including Forbes, Nature Biotechnology, Endpoints News, and more.
References
